We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Avantor Broadens RIM Single-Use Bioprocessing Reach in APAC
Read MoreHide Full Article
Key Takeaways
Avantor expands RIM single-use bioprocessing products across APAC with local manufacturing in China.
Local sourcing and regional supply chains aim to improve reliability and customization for Avantor.
Avantor's BMP segment posted double-digit order growth and a 1.1x book-to-bill ratio in second-quarter 2026.
Avantor, Inc. (AVTR - Free Report) recently expanded the availability of RIM single-use bioprocessing portfolio across the Asia Pacific (APAC) region, strengthening its presence in a key biopharma manufacturing market. The move aims to provide regional customers with greater access to locally manufactured bioprocessing solutions tailored to their production needs.
The expansion aligns with management's broader Revival strategy, which emphasizes commercial execution, manufacturing productivity and bioprocessing growth. During the second quarter of 2026, management highlighted strong order trends in the Bioscience & Medtech Products segment and increased investments in manufacturing capabilities, suggesting that deeper APAC penetration could support long-term growth in higher-value bioprocessing business.
Likely Trend of AVTR Stock Following the News
Following the announcement, shares of AVTR traded flat in yesterday’s trading. Year to date, shares of the company have gained 38.4% compared with the industry’s 3.4% growth. The S&P 500 has risen 10.1% in the same timeframe.
The APAC expansion is likely to strengthen Avantor's long-term growth by deepening its position in the fast-growing bioprocessing market while reinforcing its regional manufacturing strategy. By producing RIM single-use consumables locally in China and leveraging regional supply chains, the company can improve supply reliability, shorten lead times and better serve biopharma customers with customized solutions.
AVTR currently has a market capitalization of $10.56 billion.
Image Source: Zacks Investment Research
More on the News
The expanded RIM portfolio broadens Avantor’s offerings in the rapidly growing bioprocessing market across APAC. The portfolio includes a range of single-use consumables such as bioprocessing bags, assemblies, tubing and components, as well as mixing and storage hardware used across multiple biomanufacturing applications. By increasing access to these products throughout the region, Avantor aims to help biopharmaceutical manufacturers improve operational efficiency, ensure continuity of supply and address specific production requirements with locally available solutions.
A key differentiator of the RIM platform is its regional manufacturing footprint. The products are manufactured at Avantor’s Changzhou, China, facility, the company’s first single-use production site in APAC. The 2,600-square-meter facility has more than two decades of experience in single-use design and manufacturing and operates under ISO 9001:2015 certification and Good Manufacturing Practice standards. Combined with local component sourcing and in-region supply chains, the facility enables Avantor to offer customers a more responsive and flexible supply model while supporting customized bioprocessing workflows. Notably, RIM products are available exclusively to APAC customers.
The announcement also complements the momentum management highlighted in Avantor’s Bioscience & Medtech Products (“BMP”) segment during second-quarter 2026 results. BMP generated double-digit order growth and a book-to-bill ratio of 1.1x, reflecting healthy demand across its portfolio and particularly strong order trends in process chemicals and fluid handling products.
Management noted that improving operations, manufacturing investments and stronger customer engagement are helping build a sustainable growth pipeline for the segment. As bioprocessing remains a core component of BMP, the broader rollout of the RIM portfolio across APAC could further strengthen Avantor’s position in the region’s expanding biologics manufacturing market while supporting the company’s expectation for BMP to return to organic growth in the second half of 2026.
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global single-use bioprocessing market size was valued at $37.8 billion in 2025 and is projected to grow from $41.1 billion in 2026 to $80.4 billion by 2033, at a CAGR of 10.1%.
The growing adoption of single-use bioprocessing technologies has been fueled by rising demand for biopharmaceuticals, alongside increasing investments in biologics development, including monoclonal antibodies, vaccines and recombinant proteins.
In July, AVTR announced that its NuSil brand has expanded the long-standing collaboration with the Population Council to support the development of a next-generation three-month dapivirine vaginal ring for HIV prevention. Under the partnership, NuSil will supply its high-purity medical-grade silicones, which are critical to the device's drug delivery performance and mechanical reliability over the extended duration.
AVTR’s Zacks Rank & Other Key Picks
Currently, AVTR has a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
Avantor Broadens RIM Single-Use Bioprocessing Reach in APAC
Key Takeaways
Avantor, Inc. (AVTR - Free Report) recently expanded the availability of RIM single-use bioprocessing portfolio across the Asia Pacific (APAC) region, strengthening its presence in a key biopharma manufacturing market. The move aims to provide regional customers with greater access to locally manufactured bioprocessing solutions tailored to their production needs.
The expansion aligns with management's broader Revival strategy, which emphasizes commercial execution, manufacturing productivity and bioprocessing growth. During the second quarter of 2026, management highlighted strong order trends in the Bioscience & Medtech Products segment and increased investments in manufacturing capabilities, suggesting that deeper APAC penetration could support long-term growth in higher-value bioprocessing business.
Likely Trend of AVTR Stock Following the News
Following the announcement, shares of AVTR traded flat in yesterday’s trading. Year to date, shares of the company have gained 38.4% compared with the industry’s 3.4% growth. The S&P 500 has risen 10.1% in the same timeframe.
The APAC expansion is likely to strengthen Avantor's long-term growth by deepening its position in the fast-growing bioprocessing market while reinforcing its regional manufacturing strategy. By producing RIM single-use consumables locally in China and leveraging regional supply chains, the company can improve supply reliability, shorten lead times and better serve biopharma customers with customized solutions.
AVTR currently has a market capitalization of $10.56 billion.
Image Source: Zacks Investment Research
More on the News
The expanded RIM portfolio broadens Avantor’s offerings in the rapidly growing bioprocessing market across APAC. The portfolio includes a range of single-use consumables such as bioprocessing bags, assemblies, tubing and components, as well as mixing and storage hardware used across multiple biomanufacturing applications. By increasing access to these products throughout the region, Avantor aims to help biopharmaceutical manufacturers improve operational efficiency, ensure continuity of supply and address specific production requirements with locally available solutions.
A key differentiator of the RIM platform is its regional manufacturing footprint. The products are manufactured at Avantor’s Changzhou, China, facility, the company’s first single-use production site in APAC. The 2,600-square-meter facility has more than two decades of experience in single-use design and manufacturing and operates under ISO 9001:2015 certification and Good Manufacturing Practice standards. Combined with local component sourcing and in-region supply chains, the facility enables Avantor to offer customers a more responsive and flexible supply model while supporting customized bioprocessing workflows. Notably, RIM products are available exclusively to APAC customers.
The announcement also complements the momentum management highlighted in Avantor’s Bioscience & Medtech Products (“BMP”) segment during second-quarter 2026 results. BMP generated double-digit order growth and a book-to-bill ratio of 1.1x, reflecting healthy demand across its portfolio and particularly strong order trends in process chemicals and fluid handling products.
Management noted that improving operations, manufacturing investments and stronger customer engagement are helping build a sustainable growth pipeline for the segment. As bioprocessing remains a core component of BMP, the broader rollout of the RIM portfolio across APAC could further strengthen Avantor’s position in the region’s expanding biologics manufacturing market while supporting the company’s expectation for BMP to return to organic growth in the second half of 2026.
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global single-use bioprocessing market size was valued at $37.8 billion in 2025 and is projected to grow from $41.1 billion in 2026 to $80.4 billion by 2033, at a CAGR of 10.1%.
The growing adoption of single-use bioprocessing technologies has been fueled by rising demand for biopharmaceuticals, alongside increasing investments in biologics development, including monoclonal antibodies, vaccines and recombinant proteins.
Avantor, Inc. Price
Avantor, Inc. price | Avantor, Inc. Quote
Other News
In July, AVTR announced that its NuSil brand has expanded the long-standing collaboration with the Population Council to support the development of a next-generation three-month dapivirine vaginal ring for HIV prevention. Under the partnership, NuSil will supply its high-purity medical-grade silicones, which are critical to the device's drug delivery performance and mechanical reliability over the extended duration.
AVTR’s Zacks Rank & Other Key Picks
Currently, AVTR has a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.